(NASDAQ:CJET), New York, NY, Oct. 27, 2025 (GLOBE NEWSWIRE) — Chijet Motor Company, Inc. (NASDAQ: CJET) (“Chijet” or the “Company”) today announced the successful closing of a private placement offering of units, consisting of ordinary shares and warrants, for gross proceeds equivalent to $300 million in cryptocurrency. The offering was conducted with select non-U.S. institutional […]

(NasdaqGM:FNWB), PORT ANGELES, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) — First Northwest Bancorp (Nasdaq: FNWB) (“First Northwest” or the “Company”), the holding company for First Fed Bank (“First Fed” or the “Bank”), today reported net income of $802,000 for the third quarter of 2025, compared to net income of $3.7 million for the second quarter

(TSX:CXI),(OTC US:CURN),(Other OTC:CURN), TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) — Currency Exchange International, Corp. (the “Group” or “CXI“) (TSX: CXI; OTCQX: CURN), announced today that its board of directors (the “Board”) has unanimously approved the adoption of a “new generation” shareholder rights plan (the “Rights Plan”) pursuant to a shareholder rights plan agreement entered into

(TSX-V:ELBM),(NASDAQ:ELBM), TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company“) has launched a new program to advance mineral deposit modelling and feedstock integration at its Iron Creek cobalt-copper project in Idaho, supporting U.S. efforts to onshore critical mineral production and reduce dependence on foreign supply

(NASDAQ:CABA), – All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators – – Myositis registrational trial being initiated this quarter with a planned cohort of 14 DM/ASyS patients and a 16-week primary endpoint –

(NASDAQ:TNXP), Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Treatment was well tolerated with minimal effects on weight or blood pressure and discontinuation rate of 19% vs. placebo of 20.8% Data support the potential of Tonmya as a well-tolerated, centrally acting, non-opioid analgesic and therapeutic option for

(NASDAQ:BBIO), – All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company's prior studies – Primary interim analysis endpoint, glycosylated αDG, significantly increased by 1.8x change from baseline at 3 months (p<0.0001), and improvements were sustained at 12 months (p<0.0001) in BBP-418 treated

(Neo:NETZ.NE),(OTC US:OFSTF),(OTCQB:OFSTF),(Boerse Frankfurt – Freiverkehr:M2Q), TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) — Carbon Streaming Corporation (Cboe CA: NETZ) (OTCQB: OFSTF) (FSE: M2Q) (“Carbon Streaming” or the “Company“) today announced that it has appointed Jonathan Rubenstein, LLB, as expert consultant to the Company to provide oversight, guidance and strategic direction to the Company for significant litigation.

(NASDAQ:NTRB),(NASDAQ:NTRBW), ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company founder, Gareth Sheridan has returned as Company CEO. During the period of August 10 until October 27 , Co-Founder and Chairman, Serguei Melnik had taken over the responsibilities of CEO. Mr Sheridan has returned to the position of CEO

SAN JOSE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) — interface.ai, the first BankGPT platform powering the most capable AI agents for banks and credit unions, today announced the appointment of Steve Swanston as Chief Revenue Officer (CRO). Swanston's appointment marks a significant milestone in interface.ai's growth journey as the company scales its AI platform and